^詳情請向店員查詢。 *對於4至12歲近視兒童的治療結果，可能會因開始使用MiYOSMART iQ治療時的年齡組別及其他參數而有所不同。臨床顯著近視進展定義為睫狀肌麻痺下等效球面屈光度數增加0.50D或以上。 #數據來源：由香港理工大學眼科視光學院近視研究中心進行的一項雙盲、安慰劑對照、隨機對照臨床試驗，研究為期12個月，共有196名年齡介乎4至12歲之間，符合條件的近視學童完成評估，並按年齡分層後以1:1:1比例隨機分配至三個鏡片組別（DIMS TED、DIMS及單光鏡片）接受測試。平均而言，DIMS TED組別在12個月內未見近視出現臨床顯著加深；DIMS TED組別在12個月內的眼軸增長低於或相若於正視眼的正常生理性增長。詳情請參 閱：https://eppro02.ativ.me/web/index.php?page=IntHtml&project=ARVO26&id=4486941。   1.Tse DY, Hon Y, Chun RK, et al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523,  ARVO 2026 Annual Meeting, Denver, USA. https://eppro02.ativ.me/web/index.php?page=IntHtml&project=ARVO26&id=4486941(accessed date 27.05.2026)   2.HOYA data on file. MiYOSMART iQspectacle lens clinical outcomes. 04/2026.   3.Kaymak H, DevenijnM, Tse DY, et al. Defocus Incorporated Multiple Segments Spectacle Lenses with Triple Enhanced Design Normalize and Neutralize Axial Elongation in Myopic Children: A Randomized Three-Arm Trial Using  AMMC Physiological Growth Criteria. Abstract OD72, ARVO Annual Meeting 2026, Denver, USA. https://eppro02.ativ.me/web/index.php?page=IntHtml&project=AR VO26&id=4490935 (accessed date 27.05.2026)   4.Tse DYY, Chun RKM, Hon Y, et. al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Triple Enhanced Design Spectacle Lenses. The 41st Asia-Pacific Academy of Ophthalmology Congress, 2026, https://2026.apaophth.org/abstract/?code=205567 (accessed date 27.05.2026)   5.Smith III EL, Arumugam B, Hung LF, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res. 2020;177:32-40. DOI: 10.1016/j.visres.2020.08.003.   6.Swiatczak B, Scholl HPN, Schaeffel F. Retinal ‘sweet spot’ for myopia treatment. Sci Rep 14, 26773 (2024). https://doi.org/10.1038/s41598-024-78300-x